Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.45 |
| ▸ | FDPS | P14324 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301803 | 0.80 | CA1 (0.54) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL10942476 | 0.80 | CA1 (0.54) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL5488054 | 0.78 | CA1 (0.52) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL17255716 | 0.78 | CA1 (0.52) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL28153784 | 0.78 | CA1 (0.52) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL17292836 | 0.78 | CA1 (0.52) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL17292835 | 0.78 | CA1 (0.52) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL3935320 | 0.78 | CA1 (0.52) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL11797173 | 0.78 | CA1 (0.52) | CA1ACE2SPHK1FFAR1FFAR4 | |
| SCHEMBL3942651 | 0.78 | CA1 (0.52) | CA1ACE2SPHK1FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191220-A1 | COMPOSITIONS AND METHODS COMPRISING SERINE PROTEASE VARIANTS | DANISCO US INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11898177-B2 | Variant maltohexaose-forming alpha-amylase variants | DANISCO US INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230049452-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2023-02-16 | — | — | US | disclosed |
| US-20220204959-A1 | COMPOSITIONS AND METHODS COMPRISING PROTEASE VARIANTS | DANISCO US INC (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220002696-A1 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20210071113-A1 | FABRIC AND HOME CARE PRODUCTS | PROCTER & GAMBLE (US) | 2021-03-11 | — | — | US | disclosed |
| US-10920204-B2 | Compositions and methods comprising a lipolytic enzyme variant | DANISCO US INC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10900000-B2 | Fabric and home care products comprising cold water proteases | THE PROCTER & GAMBLE COMPANY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10865398-B2 | Compositions and methods comprising a lipolytic enzyme variant | DANISCO US INC (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200299618-A1 | COMPOSITIONS AND METHODS COMPRISING SERINE PROTEASE VARIANTS | PROCTER & GAMBLE (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2705145-A2 | COMPOSITIONS AND METHODS COMPRISING SERINE PROTEASE VARIANTS | The Procter and Gamble Company (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130260438-A1 | COMPOSITIONS AND METHODS COMPRISING SERINE PROTEASE VARIANTS (AS AMENDED) | DANISCO US INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2566960-A1 | CONSUMER PRODUCTS WITH PROTEASE VARIANTS | The Procter & Gamble Company (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2013033318-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | DANISCO US INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012151480-A2 | COMPOSITIONS AND METHODS COMPRISING SERINE PROTEASE VARIANTS | THE PROCTER & GAMBLE COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-2510092-A1 | FABRIC AND HOME CARE PRODUCTS | The Procter & Gamble Company (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011140316-A1 | CONSUMER PRODUCTS WITH PROTEASE VARIANTS | THE PROCTER & GAMBLE COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110262999-A1 | Compositions and Methods Comprising Protease Variants | DANISCO US INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110237487-A1 | FABRIC AND HOME CARE PRODUCTS | THE PROCTER & GAMBLE COMPANY | 2011-09-29 | — | — | US | disclosed |
| WO-2011072117-A1 | FABRIC AND HOME CARE PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262999-A1 | Compositions and Methods Comprising Protease Variants | PRSS3, PRSS1, PRSS2 | CA1 1254/4885ACE2 128/4885SPHK1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.